Healio
Healio
CTS banner

Clinical Trials at the Summit meeting
ByCarolyn Sasse
BySara Kellner
ByDavid W. Mullin
Fact checked byChristine Klimanskis, ELS

Read more

July 07, 2024
2 min watch
Save

VIDEO: Astellas offers updates on Izervay safety, phase 1 geographic atrophy trial

ByCarolyn Sasse
BySara Kellner
ByDavid W. Mullin
Fact checked byChristine Klimanskis, ELS
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Carolyn Sasse of Astellas highlights the company’s ophthalmology pipeline.

Sasse provides updates about post-marketing safety data for Izervay (avacincaptad pegol intravitreal solution) and a phase 1 trial that is currently recruiting patients with geographic atrophy secondary to age-related macular degeneration.

“Over the past decade, we have established a leading early-stage ophthalmology pipeline that includes cell and gene therapies to treat diseases such as geographic atrophy and glaucoma, as well as inherited retinal diseases such as Stargardt and retinitis pigmentosa,” she said.

Sources/Disclosures

Collapse
Source:

Healio Interviews

Disclosures: Sasse reports being the development head of cell and gene therapy at Astellas.

Read more about

age-related macular degeneration
geographic atrophy
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

 

Related Content